Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with <i>MYD88</i> L265P mutation
Ivan Dlouhy,
Marc Armengol,
Clara Recasens-Zorzo,
Marcelo L Ribeiro,
Patricia Pérez-Galán,
Francesc Bosch,
Armando López-Guillermo,
Gaël Roué
Affiliations
Ivan Dlouhy
Department of Hematology, Hospital Clínic, BarceIona, Spain; Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona
Marc Armengol
Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
Clara Recasens-Zorzo
Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona
Marcelo L Ribeiro
Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain; Post Graduate Program in Health Science, Universidade São Francisco (USF), Bragança Paulista
Patricia Pérez-Galán
Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona
Francesc Bosch
Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona
Armando López-Guillermo
Department of Hematology, Hospital Clínic, BarceIona, Spain; Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona
Gaël Roué
Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
